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Background: Human papillomavirus (HPV) infection accounts for about 40–50% of all cases of penile carcinoma
suggesting that other factors, including host genetic status, are involved in neoplastic transformation. In this
perspective, STK11 gene, which has been found frequently mutated in HPV-related cervical carcinoma, has been
analyzed in HPV-positive and HPV-negative invasive penile cancers to establish its mutational status and the
possible correlation of HPV infection with specific genetic alterations.
Methods: Genomic DNAs extracted from 26 cases of penile squamous cell carcinoma were analyzed for genetic
alterations in the exons 1 to 9 of STK11 gene by quantitative real-time PCR. Ratios of potentially deleted and
non-deleted exons were indicative of specific loss of STK11 coding regions. DNA samples of 5 cancer cases were
subjected to standard PCR amplification of STK11 exons 1 to 9 and analyzed for somatic mutations by direct
nucleotide sequencing analysis.
Results: Heterozygous deletions of STK11 exon 1 and 2 were identified in 2 out of 14 HPV-positive (14.3%) and 1
out of 12 HPV-negative cases (8.3%). Complete nucleotide sequencing analysis of exons 1 to 9 showed a single
nucleotide change upstream the exon 2 coding region in 1 out of 5 penile carcinoma samples.
Conclusions: The present results suggest that single nucleotide mutations and/or deletions of STK11 gene are rare
events in penile cancer. Moreover, no significant association was observed between STK11 alterations and HPV
infection in these tumors.
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Penile cancer is a rare malignancy in Western Europe
and the United States with age-standardized incidence
rates (ASR) of 0.1–1.5 per 100,000 men. In Africa, Asia
and South America, however, the estimate ASRs are sig-
nificantly higher with peaks of 2.8 and 3.7 per 100,000
men, in Uganda and Brazil, respectively [1].
The most common histological type of penile carcinoma
is the squamous cell carcinoma (95%) which comprises
several subtypes such as usual squamous cell carcinoma
(48–65%), basaloid (4–10%), warty (7–10%), verrucous
(3–8%), papillary (5–15%) and mixed carcinoma (9–10%)* Correspondence: m.tornesello@istitutotumori.na.it
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distribution, and reproduction in any medium[2]. Although the etiology of penile cancer is not yet fully
understood several risk factors, such as poor hygiene and
phimosis, lack of circumcision in childhood and history of
smoking, have been shown to increase the risk to develop
this malignancy [3-6]. Human papillomaviruses (HPV)
have been associated with approximately 47% of invasive
penile carcinoma cases with HPV16 and HPV18 as the
most common viral genotypes accounting for 60.23% and
13.35%, respectively, of the HPV attributable cases [7].
Higher rates of HPV positivity have been found in warty-
basaloid (82%), basaloid (76%), and warty carcinomas
(39%). This observation was indicative of a strong associ-
ation between the basaloid cell type and presence of
HPV [8].
Several studies have reported genetic alterations in tumor
suppressor genes and oncogenes, in both HPV-positive andtral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.
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in tumor carcinogenesis [9,10]. STK11 is a 23 kb tumor
suppressor gene, mapped to chromosome 19p13.3, which
encodes for the serine/threonine kinase 11 (STK11) also
known as liver kinase B1 (LKB1) or renal carcinoma
antigen NY-REN-19 [11,12]. The STK11 gene is widely
expressed in embryonic and adult tissues and the
encoded STK11 kinase is an essential regulator of
chromatin remodeling, cell cycle arrest, p53-dependent
apoptosis, Wnt signaling, cell polarity and energy me-
tabolism [13-15]. Germ-line mutations of the STK11
gene are associated with Peutz-Jeghers syndrome (PJ)
[11,12], an autosomal dominant disorder characterized
by hamartomatous polyps of the gastrointestinal tract
and by a considerably increased risk of cancer in
gastrointestinal tract, pancreas, breast, lung, uterus,
cervix, ovary and testis [16-18]. PJ patients are at
increased risk to develop cancer particularly at body
sites with higher levels of STK11 enzyme in the normal
tissue [19].
Somatic mutations of STK11gene have been frequently
found in several sporadic tumors, including HPV-related
cervical cancer [20-25]. No studies have been performed
on STK11 mutational status in penile carcinoma.
The aim of the present study was to analyze genetic
alterations and single nucleotide mutations in exons 1 to
9 of STK11 gene in HPV-positive and HPV-negative
penile cancers to possibly establish a relationship be-
tween HPV infection and genetic alterations involved in
cancer progression.Methods
Samples and DNA isolation
This study included DNA samples extracted from
liquid-nitrogen frozen specimen of penile squamous cell
carcinoma (n = 6) from Black Ugandan patients andTable 1 Primer sequences used for PCR, nucleotide sequence
1 to 9
Region Forward (5’-3’) Reverse (5
STK11 exon 1 ACAATCGTTTCTGTTGGAAG TCCTTGTGT
STK11 exon 2 CTCTAGGGAAGGGAGGAG TTTCTGCTT
STK11 exon 3 TGAGCTGTGTGTCCTTAG CACTGGGA
STK11 exon 4 CCCGCAGGTACTTCTGTC GTGGTGAG
STK11 exon 5 CCTGAGGGCTGCACGGCACC GGGGCGGG
STK11 exon 6 TCGAAATGAAGCTACAACATC TTTCAGCAG
STK11 exon 7 TTCTCCTCAGGGATGCTTG CACCTGTGC
STK11 exon 8 ATGACTGTGGTGCCGTAC CCGTGAAG
STK11 exon 9 CAGGACAGGTCCCAGAAGAG CCAGCCTCparaffin-embedded penile squamous cell carcinoma (n =
20) from Caucasian Italian patients. These samples were
previously characterized in terms of histology, DNA
quality, HPV genotypes, HPV16 variants and viral inte-
gration status [9,26]. The study protocol was approved
by the ethical review board of the involved Institution.
Genomic DNA was extracted from frozen biopsies as
well as from thin sections of fixed and embedded tissues
according to published procedures [27,28]. In particular
two 10 μm sections of each biopsy were extracted twice
with 1 ml of xylenes, for paraffin removal, and twice
with 500 μl of 100% ethanol, for organic solvents re-
moval. Both xylenes-treated and fresh tissue samples
were digested with Proteinase K (150 μg per ml at 60°C
for 30 min) in 100–500 μl lysis buffer (10 mM Tris–HCl
pH 7.6, 5 mM EDTA, 150 mM NaCl, 1% SDS), followed
by DNA purification by phenol and phenol-chloroform-
isoamyl alcohol (25:24:1) extraction and ethanol precipi-
tation in 0.3 M sodium acetate (pH 4.6). Genomic DNA
was also extracted from PC23, HeLa and SiHa cell lines
to be used as positive and negative control, respectively,
in the PCR and real time PCR.Quantitative real-time PCR
Exons 1 to 9 of STK11 gene were independently ampli-
fied by real time polymerase chain reaction (PCR) using
primer sequences listed in Table 1. The nine primer
pairs have been designed with Beacon Designer 7.9 (Bio
Rad Laboratories, Inc). All STK11 exons were amplified
in a total volume of 25 μl containing iQ SYBR Green
Supermix containing 50 mM KCl, 20 mM Tris–HCl,
pH 8.4, 0.2 mM of each dNTP and 25 units/ml iTaq
DNA polymerase, 3 mM MgCl2, 10 nM SYBR Green I
(Bio-Rad Laboratories, Inc), 3 μmol/L of each primer,
and 100 ng – 500 ng of genomic DNA. All experiments
were performed on the CFX96 Real Time Systemanalysis and Real-time PCR amplification of STK11 exons
’-3’) Product length Annealing
temperature (°C)
TCCGACTTC 113 bp 55
CTCTTCGTTG 201 bp 61
AACGCTTCTC 102 bp 60
CAGCAGGTTC 100 bp 61
GCACTTACAGG 180 bp 69
GTCAGAGAG 138 bp 61
TGCCGGATC 71 bp 60
TCCTGAGTGTAG 100 bp 61
ACTGCTGCTT 203 bp 67
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cation was confirmed applying dissociation analysis
starting at 65°C.
A 5-log dilution series of genomic DNA, extracted
from the cell line PC23 [29], were amplified in each ex-
periment for the construction of an absolute standard
curve. This curve was used to determine the copy num-
ber of exon 1(test) and exon 7 (reference) of STK11 gene
in the unknown samples. All PCR reactions were set up
in duplicate.
Deletions of STK11 regions were verified by calculat-
ing the ratios (R) of potentially deleted and non-deleted
exons. Values of R between 0 and 0.3 and between 0.4
and 0.7 are assumed to be indicative of homozygous or
heterozygous deletions, respectively; values of R between
0.8 and 1.2 indicate no changes of the copy number in
the two exons.
Mutation analysis of STK11 gene
Exons 1 to 9 of STK11 gene were independently ampli-
fied by polymerase chain reaction (PCR). All primer sets,
described in Table 1, were used to perform standard
PCR reactions in 50 μl reaction mixture containing 100–Figure 1 Quantitative Real-time PCR of exon 1 and exon 7 of STK11 g
STK11 gene. Standard curves of 5-log dilution genomic DNA (PC23 cell line
STK11 gene in the unknown samples.500 ng of target DNA, Hot Master buffer containing
2.5 mM MgCl2, 20 pmol of each primer, 200 μM of
dNTPs mix and 1.25 units of thermostable Taq DNA
polymerase (5-Prime GmbH, Hamburg, DE). DNA was
amplified in a Perkin-Elmer GenAmp PCR System 9700
thermal cycler with the following steps: an initial 2 min
denaturation at 94°C, followed by 36 cycles of 30 s at 94°C,
30 s at the annealing temperature specified in Table. 1,
72°C for 30 s, and a final elongation at 72°C for 5 min.
A reaction mixture without template DNA was included
in each PCR run, as negative control. All products were
analyzed by electrophoresis on 7% plyacrylamide gels to
verify the specificity of the PCR product. Amplimers of
STK11 exons 1–9 from 5 samples were subjected to auto-
mated direct nucleotide sequence analysis at Primm
Laboratories (Milan, IT) using the same primers used
for PCR amplification. STK11 mutations were sought
by comparison analysis with the NG_007460.1 reference
sequence present in the GenBank.
Results
Fourteen HPV-positive (53.9%) and twelve HPV-negative
(46.2%) penile squamous cell carcinoma samples wereene in penile cancers. Amplification of exon 1 (A) and exon 7 (C) of
) used to determine the copy number of exon 1(B) and exon 7 (D) of
Table 2 List of penile cancer samples analysed for exon’s deletions
Sample HPV Exon 1 copy number Exon 7 copy number Exon 1/Exon 7 ratio Change of exon 1 copy number Origin
PC04 HPV16 3.0 × 104 3.1 × 104 1 no change Uganda
PC07 HPV16 3.6 × 104 3.5 × 104 1 no change Uganda
PC08 HPV16 2.1 × 103 2.2 × 103 1 no change Uganda
PC15 HPV16 4.0 × 104 4.2 × 104 1 no change Uganda
PC17 HPV16 2.8 × 103 2.7 × 103 1 no change Uganda
PC23 HPV16 4.0 × 103 3.8 × 103 1.1 no change Uganda
PC30 HPV16 480 457 1.1 no change Italy
PC31 Negative 648 651 1 no change Italy
PC32 HPV16 787 840 0.9 no change Italy
PC33 Negative 637 765 0.8 no change Italy
PC34 Negative 838 943 0.9 no change Italy
PC35 HPV 18 487 847 0.5 heterozygous deletion Italy
PC36 HPV16 950 975 1 no change Italy
PC37 HPV16 655 645 1 no change Italy
PC38 HPV16 780 795 1 no change Italy
PC79 HPV16 501 495 1 no change Italy
PC80 Negative 457 432 1.1 no change Italy
PC81 Negative 380 347 1.1 no change Italy
PC82 Negative 468 310 1.4 no change Italy
PC84 Negative 930 971 1 no change Italy
PC85 HPV56/54 172 316 0.5 heterozygous deletion Italy
PC90 Negative 215 475 0.4 heterozygous deletion Italy
PC91 Negative 697 846 0.8 no change Italy
PC92 Negative 461 553 0.8 no change Italy
PC93 Negative 738 643 1.1 no change Italy
PC94 Negative 806 780 1 no change Italy
PC17 Intron 2 nt 17’587 C>T  
Figure 2 DNA sequence electropherogram showing C to T
transition at nucleotide 17587 in intron 2 of STK11 gene.
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specific primer sets designed to individually amplify
exons 1 to 9. While exons 3 to 9 were always amplified,
exons 1 and 2 were not efficiently amplified in 3 out of
26 (11.5%) samples. All 26 samples were subjected to a
further quantitative real-time PCR using primer pairs
specific for exon 1 (test) and for exon 7 (reference) to
determine an absolute quantification of genomic equiva-
lents of exon 1 and exon 7 in each sample. A 5-log dilu-
tion series of genomic DNA, extracted from the cell line
PC23, was also amplified in the same reaction set to ob-
tain an amplification standard curve (Figure 1). As
expected, in 23 out of 26 samples the ratio of exon 1/
exon 7 copy number was R ≥ 0.8, indicating no deletions
in exon 1. In three out of 26 cases the ratio of exon 1/exon
7 was R ≈ 0.5, indicating the presence of an heterozygous
deletion in the test exon. In particular, STK11 deletions
were identified in 2 out of 14 HPV positive (14.3%) and 1
out of 12 HPV-negative cases (8.3%) (Table 2). All three
STK11 deleted cases were of Italian origin.
Annunziata et al. Infectious Agents and Cancer 2013, 8:2 Page 5 of 6
http://www.infectagentscancer.com/content/8/1/2Moreover, nucleotide sequencing analysis of the whole
coding region (exons 1 to 9) of STK11 gene was per-
formed in 5 samples. A single nucleotide mutation, con-
sisting of C to T transition at position 17587 in the
intronic region 2 was detected in one case from Uganda
out of 5 (20%) total samples analyzed (Figure 2).
Discussion
The knowledge of genetic alterations in penile cancer is
limited. In this study we investigated STK11 somatic
mutations in both HPV-positive and HPV-negative
penile squamous cell carcinoma cases, in order to verify
a potential role of this tumor suppressor gene in penile
tumorigenesis. The results obtained in our study showed
that STK11 exon 1 and 2 are deleted in 11.5% of penile
cancers. In particular, heterozygous deletions of STK11
exons 1 and 2 were observed in 14.3% of HPV-positive
and in 8.3% of HPV-negative tumors, indicating that
HPV status has no effect on the genetic alteration of
STK11 gene.
Genetic alterations of STK11gene have been identified
in many sporadic cancers and derived cell lines, includ-
ing HPV-related cervical carcinoma. In particular, Wingo
et al. showed that up to 20% of cervical cancers har-
bored somatic mutations in STK11 coding regions, of
which approximately one-half were single nucleotide
substitutions or small deletions while the other half con-
sisted of larger monoallelic or biallelic deletions [25].
Moreover they showed that the inactivation of this gene
was associated with accelerated disease progression.
Furthermore, an homozygous deletion of whole or of
part of STK11gene was observed in SiHa and HeLa cell
line [24,25].
The nucleotide sequence analysis of exons 1 to 9 of
STK11 in 5 penile carcinoma cases showed no somatic
mutations in none of the 9 coding regions. A single nu-
cleotide substitution was identified in the intron 2 of
one cancer case, however it seems to have no effect on
the expression of the protein. Somatic mutations, affect-
ing conserved residues within the kinase domain or in-
tron/exon junctions of STK11, were previously identified
in 4 out of 6 cases (66.7%) of cervical adenocarcinomas
and 2 out of 10 cases (20%) of squamous cell carcin-
omas, indicating that single nucleotide substitutions are
frequent events in a specific histological subtype of cer-
vical cancer [25].
Very few studies are available on somatic mutations of
other genes in penile carcinoma. A recent report showed
a dysregulation of phosphatidylinositol 3-kinase and
Ras pathways through somatic alterations of the
PIK3CA, HRAS and KRAS genes in 11 out of 28 (39%)
penile cancer samples, without any statistically signifi-
cant difference between HPV-positive and HPV-negative
cases [30].Other studies analyzing genetic alterations in TP53
gene of penile carcinomas reported mutations in frac-
tions varying from 8% to 33% of the cases [31-35]. Fur-
thermore, most of reported alterations consist in single
nucleotide mutations that cause amino acid substitution
in the corresponding protein.
Conclusions
The present study has the limitation to analyze a modest
sample size, but has the advantage to include cancer
cases from high incidence (Uganda) and low incidence
(Italy) geographic regions. The results obtained so far
allow to conclude that single nucleotide mutations and/
or deletion of STK11 gene are rare events in penile car-
cinoma suggesting that STK11 genetic alterations do not
have a relevant role in the pathogenesis of penile cancer.
Abbreviations
HPV: Human Papillomavirus; STK11: Serine/threonine kinase 11; LKB1: Liver
kinase B1.
Competing interests
The authors report no competing of interests.
Authors’ contribution
MLT and FMB were responsible for the overall planning and coordination of
the study. LB contributed to the data analysis. SL carried out the
histopathology evaluation of the cases. CA was responsible for specimen
processing, DNA analysis and with MLT compiled and finalized the
manuscript. All authors read and approved the final manuscript.
Acknowledgements
This work was supported by grants from the Ministero della Salute
(Programma Integrato Oncologia RO4/2007) and from the ICSC-World
Laboratory (project MCD-2/7).
Author details
1Molecular Biology and Viral Oncology, National Cancer Institute "Fond.
Pascale", Cappella Cangiani, 80131, Naples, Italy. 2Department of Pathology,
National Cancer Institute "Fond. Pascale", Naples, Italy.
Received: 13 December 2012 Accepted: 7 January 2013
Published: 10 January 2013
References
1. Curado MP, Edwards B, Shin HR, Ferlay J, Heanue M, Boyle P, Storm H: Cancer
Incidence in Five Continents. Lyon: IARC Scientific Publications N° 160; 2007.
2. Chaux A, Cubilla AL: Advances in the pathology of penile carcinomas.
Hum Pathol 2012, 43:771–789.
3. Dillner J, Meijer CJ, von Krogh G, Horenblas S: Epidemiology of human
papillomavirus infection. Scand J Urol Nephrol Suppl 2000, 205:194–200.
4. Daling JR, Madeleine MM, Johnson LG, Schwartz SM, Shera KA, Wurscher
MA, Carter JJ, Porter PL, Galloway DA, McDougall JK, Krieger JN: Penile
cancer: importance of circumcision, human papillomavirus and smoking
in in situ and invasive disease. Int J Cancer 2005, 116:606–616.
5. Bleeker MC, Heideman DA, Snijders PJ, Horenblas S, Dillner J, Meijer CJ:
History of circumcision, medical conditions, and sexual activity and risk
of penile cancer. World J Urol 2009, 27:141–150.
6. Maden C, Sherman KJ, Beckmann AM, Hislop TG, Teh CZ, Ashley RL, Daling
JR: Penile cancer: epidemiology, pathogenesis and prevention. J Natl
Canc Inst 1993, 85:19–24.
7. Miralles-Guri C, Bruni L, Cubilla AL, Castellsague X, Bosch FX, De SS: Human
papillomavirus prevalence and type distribution in penile carcinoma.
J Clin Pathol 2009, 62:870–878.
8. Cubilla AL, Lloveras B, Alejo M, Clavero O, Chaux A, Kasamatsu E, Velazquez
EF, Lezcano C, Monfulleda N, Tous S, Alemany L, Klaustermeier J, Munoz N,
Annunziata et al. Infectious Agents and Cancer 2013, 8:2 Page 6 of 6
http://www.infectagentscancer.com/content/8/1/2Quint W, De SS, Bosch FX: The basaloid cell is the best tissue marker for
human papillomavirus in invasive penile squamous cell carcinoma: a
study of 202 cases from Paraguay. Am J Surg Pathol 2010, 34:104–114.
9. Annunziata C, Buonaguro L, Buonaguro FM, Tornesello ML: Characterization
of the human papillomavirus (HPV) integration sites into genital cancers.
Molecular and genetic pathways in penile cancer. Pathol Oncol Res 2012,
18:803–808.
10. Kayes O, Ahmed HU, Arya M, Minhas S: Molecular and genetic pathways
in penile cancer. Lancet Oncol 2007, 8:420–429.
11. Hemminki A, Avizienyte E, Roth S, Loukola A, Aaltonen LA, Jarvinen H, Dela
CA: A serine/threonine kinase gene defective in Peutz-Jeghers
syndrome. Duodecim 1998, 114:667–668.
12. Jenne DE, Reimann H, Nezu J, Friedel W, Loff S, Jeschke R, Muller O, Back W,
Zimmer M: Peutz-Jeghers syndrome is caused by mutations in a novel
serine threonine kinase. Nat Genet 1998, 18:38–43.
13. Alessi DR, Sakamoto K, Bayascas JR: LKB1-dependent signaling pathways.
Annu Rev Biochem 2006, 75:137–163.
14. Marignani PA: LKB1, the multitasking tumour suppressor kinase. J Clin
Pathol 2005, 58:15–19.
15. Ollila S, Makela TP: The tumor suppressor kinase LKB1: lessons from
mouse models. J Mol Cell Biol 2011, 3:330–340.
16. Boardman LA, Thibodeau SN, Schaid DJ, Lindor NM, McDonnell SK, Burgart
LJ, Ahlquist DA, Podratz KC, Pittelkow M, Hartmann LC: Increased risk for
cancer in patients with the Peutz-Jeghers syndrome. Ann Intern Med
1998, 128:896–899.
17. Giardiello FM, Welsh SB, Hamilton SR, Offerhaus GJ, Gittelsohn AM, Booker
SV, Krush AJ, Yardley JH, Luk GD: Increased risk of cancer in the Peutz-
Jeghers syndrome. N Engl J Med 1987, 316:1511–1514.
18. Giardiello FM, Brensinger JD, Tersmette AC, Goodman SN, Petersen GM,
Booker SV, Cruz-Correa M, Offerhaus JA: Very high risk of cancer in familial
Peutz-Jeghers syndrome. Gastroenterology 2000, 119:1447–1453.
19. Conde E, Suarez-Gauthier A, Garcia-Garcia E, Lopez-Rios F, Lopez-Encuentra
A, Garcia-Lujan R, Morente M, Sanchez-Verde L, Sanchez-Cespedes M:
Specific pattern of LKB1 and phospho-acetyl-CoA carboxylase protein
immunostaining in human normal tissues and lung carcinomas. Hum
Pathol 2007, 38:1351–1360.
20. Kuragaki C, Enomoto T, Ueno Y, Sun H, Fujita M, Nakashima R, Ueda Y,
Wada H, Murata Y, Toki T, Konishi I, Fujii S: Mutations in the STK11 gene
characterize minimal deviation adenocarcinoma of the uterine cervix.
Lab Invest 2003, 83:35–45.
21. Matsumoto S, Iwakawa R, Takahashi K, Kohno T, Nakanishi Y, Matsuno Y,
Suzuki K, Nakamoto M, Shimizu E, Minna JD, Yokota J: Prevalence and
specificity of LKB1 genetic alterations in lung cancers. Oncogene 2007,
26:5911–5918.
22. Kim CJ, Cho YG, Park JY, Kim TY, Lee JH, Kim HS, Lee JW, Song YH, Nam SW,
Lee SH, Yoo NJ, Lee JY, Park WS: Genetic analysis of the LKB1/STK11 gene
in hepatocellular carcinomas. Eur J Cancer 2004, 40:136–141.
23. Kenanli E, Karaman E, Enver O, Ulutin T, Buyru N: Genetic alterations of the
LKB1 gene in head and neck cancer. DNA Cell Biol 2010, 29:735–738.
24. McCabe MT, Powell DR, Zhou W, Vertino PM: Homozygous deletion of the
STK11/LKB1 locus and the generation of novel fusion transcripts in
cervical cancer cells. Canc Genet Cytogenet 2010, 197:130–141.
25. Wingo SN, Gallardo TD, Akbay EA, Liang MC, Contreras CM, Boren T,
Shimamura T, Miller DS, Sharpless NE, Bardeesy N, Kwiatkowski DJ, Schorge
JO, Wong KK, Castrillon DH: Somatic LKB1 mutations promote cervical
cancer progression. PLoS One 2009, 4:e5137.
26. Tornesello ML, Duraturo ML, Losito S, Botti G, Pilotti S, Stefanon B, De PG,
Gallo A, Buonaguro L, Buonaguro FM: Human papillomavirus genotypes
and HPV16 variants in penile carcinoma. Int J Cancer 2008, 122:132–137.
27. Fredricks DN, Relman DA: Paraffin removal from tissue sections for
digestion and PCR analysis. Biotechniques 1999, 26:198–200.
28. Tornesello ML, Buonaguro FM, Meglio A, Buonaguro L, Beth-Giraldo E,
Giraldo G: Sequence variations and viral genomic state of human
papillomavirus type 16 in penile carcinomas from Ugandan patients.
J Gen Virol 1997, 78(Pt 9):2199–2208.
29. Gentile G, Giraldo G, Stabile M, Beth-Giraldo E, Lonardo F, Kyalwazi SK,
Perone L, Ventruto V: Cytogenetic study of a cell line of human penile
cancer. Ann Genet 1987, 30:164–169.
30. Andersson P, Kolaric A, Windahl T, Kirrander P, Soderkvist P, Karlsson MG:
PIK3CA, HRAS and KRAS gene mutations in human penile cancer. J Urol
2008, 179:2030–2034.31. Levi JE, Rahal P, Sarkis AS, Villa L: Human papillomavirus DNA and p53
status in penile carcinomas. Int J Cancer 1998, 76:779–783.
32. Soufir N, Queille S, Liboutet M, Thibaudeau O, Bachelier F, Delestaing G,
Balloy BC, Breuer J, Janin A, Dubertret L, Vilmer C, Basset-Seguin N:
Inactivation of the CDKN2A and the p53 tumour suppressor genes in
external genital carcinomas and their precursors. Br J Dermatol 2007,
156:448–453.
33. Poetsch M, Hemmerich M, Kakies C, Kleist B, Wolf E, Vom DF, Hakenberg
OW, Protzel C: Alterations in the tumor suppressor gene p16(INK4A) are
associated with aggressive behavior of penile carcinomas. Virchows Arch
2011, 458:221–229.
34. Rocha RM, Ignacio JA, Jordan J, Carraro DM, Lisboa B, Lopes A, Carvalho KC, Da
CI, Cubilla A, Guimaraes GC, Vassallo J, Soares FA: A clinical, pathologic, and
molecular study of p53 and murine double minute 2 in penile
carcinogenesis and its relation to prognosis. Hum Pathol 2012, 43:481–488.
35. Yanagawa N, Osakabe M, Hayashi M, Tamura G, Motoyama T: Detection of
HPV-DNA, p53 alterations, and methylation in penile squamous cell
carcinoma in Japanese men. Pathol Int 2008, 58:477–482.
doi:10.1186/1750-9378-8-2
Cite this article as: Annunziata et al.: Somatic mutations of STK11 gene
in human papillomavirus positive and negative penile cancer. Infectious
Agents and Cancer 2013 8:2.Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
